[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
Identifieur interne : 001494 ( PubMed/Corpus ); précédent : 001493; suivant : 001495[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
Auteurs : O. Rascol ; C. Brefel-Courbon ; O. BlinSource :
- Therapie [ 0040-5957 ]
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Animals, Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Dopamine Agonists (therapeutic use), Dyskinesia, Drug-Induced (physiopathology), Humans, Levodopa (adverse effects), Parkinson Disease (drug therapy), Primates.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , pharmacology : Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- drug therapy : Parkinson Disease.
- physiopathology : Dyskinesia, Drug-Induced.
- Animals, Humans, Primates.
Abstract
Dyskinesias induced by L-dopa are involuntary and abnormal movements which lead to disablement and are observed in a lot of patients after some years of treatment. No drug has proved its efficacy for this indication. The use of D2 dopaminergic agonists as first treatment can delay their onset, delaying the need for L-dopa. New dopaminergic drugs, either with longer elimination half life or with specificity for subtypes of dopamine receptors may allow these dyskinesias to be managed more efficaciously. New non-dopaminergic, serotoninergic, adrenergic, opiate or gluamate drugs could offer antidyskinesia properties. The study of Parkinson disease's model in the methyl phenyltetrahydropyridine (MPT)-treated primate and the improvement in clinical evaluation of these dyskinesias could lead, in the short or medium term, to the discovery of new pharmarcological strategies, dealing more efficaciously with this serious adverse effect of L-dopa treatment.
PubMed: 9773099
Links to Exploration step
pubmed:9773099Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation><nlm:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 455, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C" last="Brefel-Courbon">C. Brefel-Courbon</name></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O" last="Blin">O. Blin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>1998 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:9773099</idno><idno type="pmid">9773099</idno><idno type="wicri:Area/PubMed/Corpus">001494</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001494</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation><nlm:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 455, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C" last="Brefel-Courbon">C. Brefel-Courbon</name></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O" last="Blin">O. Blin</name></author></analytic><series><title level="j">Therapie</title><idno type="ISSN">0040-5957</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Animals</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Parkinson Disease (drug therapy)</term><term>Primates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Primates</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dyskinesias induced by L-dopa are involuntary and abnormal movements which lead to disablement and are observed in a lot of patients after some years of treatment. No drug has proved its efficacy for this indication. The use of D2 dopaminergic agonists as first treatment can delay their onset, delaying the need for L-dopa. New dopaminergic drugs, either with longer elimination half life or with specificity for subtypes of dopamine receptors may allow these dyskinesias to be managed more efficaciously. New non-dopaminergic, serotoninergic, adrenergic, opiate or gluamate drugs could offer antidyskinesia properties. The study of Parkinson disease's model in the methyl phenyltetrahydropyridine (MPT)-treated primate and the improvement in clinical evaluation of these dyskinesias could lead, in the short or medium term, to the discovery of new pharmarcological strategies, dealing more efficaciously with this serious adverse effect of L-dopa treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9773099</PMID><DateCreated><Year>1998</Year><Month>11</Month><Day>03</Day></DateCreated><DateCompleted><Year>1998</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0040-5957</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>1</Issue><PubDate><MedlineDate>1998 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Therapie</Title><ISOAbbreviation>Therapie</ISOAbbreviation></Journal><ArticleTitle>[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].</ArticleTitle><Pagination><MedlinePgn>43-8</MedlinePgn></Pagination><Abstract><AbstractText>Dyskinesias induced by L-dopa are involuntary and abnormal movements which lead to disablement and are observed in a lot of patients after some years of treatment. No drug has proved its efficacy for this indication. The use of D2 dopaminergic agonists as first treatment can delay their onset, delaying the need for L-dopa. New dopaminergic drugs, either with longer elimination half life or with specificity for subtypes of dopamine receptors may allow these dyskinesias to be managed more efficaciously. New non-dopaminergic, serotoninergic, adrenergic, opiate or gluamate drugs could offer antidyskinesia properties. The study of Parkinson disease's model in the methyl phenyltetrahydropyridine (MPT)-treated primate and the improvement in clinical evaluation of these dyskinesias could lead, in the short or medium term, to the discovery of new pharmarcological strategies, dealing more efficaciously with this serious adverse effect of L-dopa treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 455, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brefel-Courbon</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Blin</LastName><ForeName>O</ForeName><Initials>O</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Pharmacologie clinique des dyskinésies induites par la L-dopa chez les malades parkinsoniens.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Therapie</MedlineTA><NlmUniqueID>0420544</NlmUniqueID><ISSNLinking>0040-5957</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011323" MajorTopicYN="N">Primates</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>10</Month><Day>17</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>10</Month><Day>17</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9773099</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001494 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001494 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:9773099
|texte= [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:9773099" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |